Ironing out the phosphorus problem.
Control of serum phosphorus remains a vexing problem in chronic kidney disease. Although novel dialysis regimens may provide excellent phosphorus control, phosphate binders remain necessary for most dialysis patients. Block et al. present a phase I clinical trial examining the safety and efficacy of SBR759, a novel non-calcium, iron-based phosphate binder. Although the risks of iron accumulation and hypocalcemia must be addressed, this phosphate binder appears to be well tolerated and effective and offers a powder-based formulation.
Zaritsky
Joshua J
JJ
Department of Pediatrics, David Geffen School of Medicine, UCLA, Los Angeles, CA, USA. jzaritsky@mednet.ucla.edu
Salusky
Isidro B
IB
D002118:Calcium / Q000097:blood / Q000378:metabolism / Q000627:therapeutic use; D002130:Calcium Phosphates / Q000627:therapeutic use; D002136:Calcium, Dietary / Q000627:therapeutic use; D006801:Humans; D006996:Hypocalcemia / Q000139:chemically induced / Q000188:drug therapy; D007676:Kidney Failure, Chronic / Q000097:blood / Q000139:chemically induced / Q000188:drug therapy; D010710:Phosphates / Q000097:blood / Q000627:therapeutic use; D010758:Phosphorus / Q000097:blood* / Q000627:therapeutic use; D016226:Phosphorus, Dietary / Q000627:therapeutic use; D006435:Renal Dialysis; D051436:Renal Insufficiency, Chronic / Q000139:chemically induced / Q000188:drug therapy; D012449:Safety
D002130:Calcium Phosphates; D002136:Calcium, Dietary; D010710:Phosphates; D016226:Phosphorus, Dietary; D010758:Phosphorus; C020243:calcium phosphate; D002118:Calcium